ArticleProstate cancer and prostatic diseases2026
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.
Jane McKenzie et al.PubMed ↗Publisher ↗
No numbers read from the abstract.